Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - famciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - famciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - famciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - famciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: silicon dioxide; sodium stearylfumarate; crospovidone; microcrystalline cellulose; copovidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - famciclovir is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours.,efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients. famciclovir is also indicated for the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older.,famciclovir is also indicated for suppression of recurrent genital herpes.,famciclovir is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients.,famciclovir is also indicated in immunocompromised patients for: ? treatment of uncomplicated herpes zoster ? treatment of recurrent herpes simplex ? suppression of recurrent herpes simplex

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - famciclovir, quantity: 250 mg - tablet, film coated - excipient ingredients: sodium stearylfumarate; silicon dioxide; copovidone; microcrystalline cellulose; crospovidone; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - famciclovir is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours.,efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients. famciclovir is also indicated for the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older.,famciclovir is also indicated for suppression of recurrent genital herpes.,famciclovir is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients.,famciclovir is also indicated in immunocompromised patients for: ? treatment of uncomplicated herpes zoster ? treatment of recurrent herpes simplex ? suppression of recurrent herpes simplex

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - famciclovir, quantity: 125 mg - tablet, film coated - excipient ingredients: silicon dioxide; crospovidone; microcrystalline cellulose; copovidone; sodium stearylfumarate; titanium dioxide; macrogol 8000; hypromellose; polydextrose; triethyl citrate - famciclovir is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours.,efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients. famciclovir is also indicated for the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older.,famciclovir is also indicated for suppression of recurrent genital herpes.,famciclovir is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients.,famciclovir is also indicated in immunocompromised patients for: ? treatment of uncomplicated herpes zoster ? treatment of recurrent herpes simplex ? suppression of recurrent herpes simplex

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharma pty ltd - famciclovir -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - famciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; hyprolose; purified water; microcrystalline cellulose; silicon dioxide; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; macrogol 4000 - for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients aged 18 years and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - famciclovir, quantity: 500 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; magnesium stearate; hyprolose; microcrystalline cellulose; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - favic is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients. favic is also indicated for the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older. favic is also indicated for suppression of recurrent genital herpes. favic is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients. favic is also indicated in immunocompromised patients for: - treatment of uncomplicated herpes zoster. - treatment of recurrent herpes simplex. - suppression of recurrent herpes simplex.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - famciclovir, quantity: 250 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - favic is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients. favic is also indicated for the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older. favic is also indicated for suppression of recurrent genital herpes. favic is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients. favic is also indicated in immunocompromised patients for: - treatment of uncomplicated herpes zoster. - treatment of recurrent herpes simplex. - suppression of recurrent herpes simplex.